Ascendis Pharma Files 6-K, Incorporates into S-8 Filings

Ticker: ASND · Form: 6-K · Filed: Mar 12, 2025 · CIK: 1612042

Sentiment: neutral

Topics: sec-filing, 6-k, registration-statement

Related Tickers: ASND

TL;DR

Ascendis Pharma (ASND) filed a 6-K on 3/12/25, incorporating it into existing S-8 filings for employee stock plans.

AI Summary

Ascendis Pharma A/S filed a Form 6-K on March 12, 2025, to report information as a foreign private issuer. The filing is incorporated by reference into several of their existing Form S-8 registration statements, which are used for employee stock plans.

Why It Matters

This filing indicates ongoing administrative and reporting activities for Ascendis Pharma, potentially related to employee stock compensation plans, which can be relevant for investors tracking corporate governance and equity dilution.

Risk Assessment

Risk Level: low — This filing is primarily administrative and does not appear to contain new material financial or operational information that would significantly alter the company's risk profile.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing by Ascendis Pharma A/S?

The Form 6-K is a report of a foreign private issuer pursuant to Section 13a-16 or 15d-16 under the Securities Exchange Act of 1934, filed for the month of March 2025.

What is the filing date of this Form 6-K?

The filing date is March 12, 2025.

What is Ascendis Pharma A/S's principal executive office address?

The principal executive offices are located at Tuborg Boulevard 12, DK-2900 Hellerup, Denmark.

Under which SEC Act is this Form 6-K filed?

This Form 6-K is filed under the Securities Exchange Act of 1934.

Which registration statements does this Form 6-K incorporate by reference?

This report is incorporated by reference into Ascendis Pharma A/S's registration statements on Form S-8, specifically Registration Numbers 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, and 333-22857.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on March 12, 2025 regarding Ascendis Pharma A/S (ASND).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing